Wu X - Search Results

1

Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).

Zhang M, Zhang Y, Song M, Xue X, Wang J, Wang C, Zhang C, Li C, Xiang Q, Zou L, Wu X, Wu C, Dong B, Xue W, Zhou Y, Chen H, Wu D, Ding K, Xu Y. Zhang M, et al. Among authors: wu x, wu d, wu c. J Med Chem. 2018 Apr 12;61(7):3037-3058. doi: 10.1021/acs.jmedchem.8b00103. Epub 2018 Apr 3. J Med Chem. 2018. PMID: 29566488

2

Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation.

Song Y, Xue X, Wu X, Wang R, Xing Y, Yan W, Zhou Y, Qian CN, Zhang Y, Xu Y. Song Y, et al. Among authors: wu x. Eur J Med Chem. 2016 Jun 30;116:13-26. doi: 10.1016/j.ejmech.2016.03.052. Epub 2016 Mar 21. Eur J Med Chem. 2016. PMID: 27043267

3

Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists.

Wu XS, Wang R, Xing YL, Xue XQ, Zhang Y, Lu YZ, Song Y, Luo XY, Wu C, Zhou YL, Jiang JQ, Xu Y. Wu XS, et al. Acta Pharmacol Sin. 2016 Nov;37(11):1516-1524. doi: 10.1038/aps.2016.32. Epub 2016 Jul 4. Acta Pharmacol Sin. 2016. PMID: 27374490 Free PMC article.

4

Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.

Zhang Y, Wu X, Xue X, Li C, Wang J, Wang R, Zhang C, Wang C, Shi Y, Zou L, Li Q, Huang Z, Hao X, Loomes K, Wu D, Chen HW, Xu J, Xu Y. Zhang Y, et al. Among authors: wu x, wu d. J Med Chem. 2019 May 9;62(9):4716-4730. doi: 10.1021/acs.jmedchem.9b00327. Epub 2019 Apr 22. J Med Chem. 2019. PMID: 30964293

5

Discovery of the First Low Nanomolar Liver Receptor Homolog-1 (LRH-1) Agonist.

Wu X, Zhang Y, Xu Y. Wu X, et al. J Med Chem. 2019 Dec 26;62(24):11019-11021. doi: 10.1021/acs.jmedchem.9b01753. Epub 2019 Nov 21. J Med Chem. 2019. PMID: 31751137

6

Discovery and optimization of novel N-benzyl-3,6-dimethylbenzo[d]isoxazol-5-amine derivatives as potent and selective TRIM24 bromodomain inhibitors with potential anti-cancer activities.

Hu Q, Wang C, Xiang Q, Wang R, Zhang C, Zhang M, Xue X, Luo G, Liu X, Wu X, Zhang Y, Wu D, Xu Y. Hu Q, et al. Among authors: wu x, wu d. Bioorg Chem. 2020 Jan;94:103424. doi: 10.1016/j.bioorg.2019.103424. Epub 2019 Nov 9. Bioorg Chem. 2020. PMID: 31776034

7

Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist.

Wu X, Shen H, Zhang Y, Wang C, Li Q, Zhang C, Zhuang X, Li C, Shi Y, Xing Y, Xiang Q, Xu J, Wu D, Liu J, Xu Y. Wu X, et al. Among authors: wu d. J Med Chem. 2021 Jun 24;64(12):8775-8797. doi: 10.1021/acs.jmedchem.1c00763. Epub 2021 Jun 14. J Med Chem. 2021. PMID: 34121397

8

Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.

Xiang Q, Wang C, Wu T, Zhang C, Hu Q, Luo G, Hu J, Zhuang X, Zou L, Shen H, Wu X, Zhang Y, Kong X, Liu J, Xu Y. Xiang Q, et al. Among authors: wu x, wu t. J Med Chem. 2022 Jan 13;65(1):785-810. doi: 10.1021/acs.jmedchem.1c01864. Epub 2021 Dec 28. J Med Chem. 2022. PMID: 34962793

9

Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.

Zhang MF, Luo XY, Zhang C, Wang C, Wu XS, Xiang QP, Xu Y, Zhang Y. Zhang MF, et al. Acta Pharmacol Sin. 2022 Oct;43(10):2735-2748. doi: 10.1038/s41401-022-00881-y. Epub 2022 Mar 9. Acta Pharmacol Sin. 2022. PMID: 35264812 Free PMC article.

10

Structure-Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors.

Li J, Zhang C, Xu H, Wang C, Dong R, Shen H, Zhuang X, Chen X, Li Q, Lu J, Zhang M, Wu X, Loomes KM, Zhou Y, Zhang Y, Liu J, Xu Y. Li J, et al. Among authors: wu x. J Med Chem. 2022 Apr 14;65(7):5760-5799. doi: 10.1021/acs.jmedchem.2c00100. Epub 2022 Mar 25. J Med Chem. 2022. PMID: 35333526

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59,153 results

Search Page

Filters